

Short Biography:

Pediatric Rheumatologist, Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health
Assistant Professor of Pediatrics, Hackensack Meridian School of Medicine
Faculty at the Center for Discovery and Innovation Hearst Foundation Physician Scientist
Guest Researcher, National Human Genome Research Institute, National Institutes of Health
Leader of the Childhood Arthritis and Rheumatology Research Alliance (CARRA)
Autoinflammatory/Periodic Fever Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)
Work Group

Dr. Lapidus has been drawn to clinical care and translational research in autoinflammatory diseases since her post graduate training under the mentorship of Dr. Daniel Kastner, the founder of autoinflammation, at the National Institutes of Health. She graduated from Barnard College, Columbia University and received her medical degree from the State University of New York Upstate Medical University. From 2014-2017, Dr. Lapidus was the Vice Chair of the CARRA SVARD (Scleroderma, Vasculitis, Autoinflammatory and Rare Disease) Committee, acting as leader of the CARRA PFAPA work group since 2013, and contributing as co-leader to the CARRA Kawasaki Disease work group. Additionally, Dr. Lapidus is a Guest Researcher at the National Human Genome Research Institute at the National Institutes of Health, where she continues her research in the pathogenesis, treatment and genetics of autoinflammatory disease with a focus on PFAPA. Her leadership of the CARRA PFAPA/Autoinflammatory Work Group includes the primary aims of improving treatment, earlier diagnosis, and supporting an infrastructure for furthering translational research in autoinflammatory diseases. Since May 2020, Dr. Sivia Lapidus has been the leader of the task force of the Hackensack Meridian Health Network dedicated to optimizing treatment, care, and research for MIS-C. Additionally, she has been a member of the American College of Rheumatology MIS-C Task Force where she contributed to generating guidance for the care of patients who are suspected of having MIS-C as well as other COVID-related hyperinflammatory conditions. She was invited to speak at the First International PFAPA Conference on June 2016 on IL-1 and the Pathogenesis of PFAPA. Publications have been on the topics of mechanisms, pathogenesis, clinical spectrum, therapeutics and genetics of PFAPA in addition to treatment of Chronic Recurrent Multifocal Osteomyelitis, Kawasaki Disease guidelines, MIS-C and Systemic Lupus Erythematosus Quality of Life.